Janssen Vaccines & Prevention B.V.
- Country
- π³π±Netherlands
- Ownership
- -
- Established
- 2000-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.crucell.com
Clinical Trials
89
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (88 trials with phase data)β’ Click on a phase to view related trials
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
- Conditions
- Influenza Prevention
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 170
- Registration Number
- NCT05901636
- Locations
- πΊπΈ
Floridian Clinical Research LLC, Miami Lakes, Florida, United States
πΊπΈJohnson County Clin-Trials, Lenexa, Kansas, United States
πΊπΈClinical Trials Managements, LLC, Metairie, Louisiana, United States
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 132
- Registration Number
- NCT05327816
- Locations
- πΊπΈ
Floridian Clinical Research LLC, Miami Lakes, Florida, United States
πΊπΈArk Clinical Research, Long Beach, California, United States
πΊπΈAccel Research Sites, DeLand, Florida, United States
A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Biological: Ad26.RSV.PreF-based Vaccine
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 755
- Registration Number
- NCT05101486
- Locations
- πΊπΈ
North Alabama Research Center, LLC, Athens, Alabama, United States
πΊπΈAchieve Clinical Research, LLC, Vestavia Hills, Alabama, United States
πΊπΈHope Research Institute, Phoenix, Arizona, United States
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
- Conditions
- COVID-19 Prevention
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 861
- Registration Number
- NCT05091307
- Locations
- πΊπΈ
Wr McCr Llc, San Diego, California, United States
π΅π±Synexus Polska Sp z o o Oddzial w Katowicach, Katowice, Poland
π΅π±Synexus Polska Sp Z O O Oddzial W Lodzi, Lodz, Poland
A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Biological: Ad26.RSV.preF-based vaccine
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 250
- Registration Number
- NCT05083585
- Locations
- πΊπΈ
Artemis Institute for Clinical Research, San Diego, California, United States
πΊπΈOptimal Research, Melbourne, Florida, United States
πΊπΈAccel Research Sites, Lakeland, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next